LITHOSTAT Drug Patent Profile
✉ Email this page to a colleague
When do Lithostat patents expire, and what generic alternatives are available?
Lithostat is a drug marketed by Mission Pharma and is included in one NDA.
The generic ingredient in LITHOSTAT is acetohydroxamic acid. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the acetohydroxamic acid profile page.
Summary for LITHOSTAT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 143 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,648 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for LITHOSTAT |
| What excipients (inactive ingredients) are in LITHOSTAT? | LITHOSTAT excipients list |
| DailyMed Link: | LITHOSTAT at DailyMed |
Recent Clinical Trials for LITHOSTAT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Data Management and Coordinating Center (DMCC) | Phase 1/Phase 2 |
| Children's Hospital of Philadelphia | Phase 1/Phase 2 |
| Nicholas Ah Mew | Phase 1/Phase 2 |
Pharmacology for LITHOSTAT
| Drug Class | Urease Inhibitor |
| Mechanism of Action | Urease Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for LITHOSTAT
US Patents and Regulatory Information for LITHOSTAT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mission Pharma | LITHOSTAT | acetohydroxamic acid | TABLET;ORAL | 018749-001 | May 31, 1983 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
